Managing CAR T-cell Related Toxicities: The Acute, The Subacute, and The Chronic

SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 46 Minutes

Overview

This program provides a comprehensive review of CAR T‑cell–related toxicities across the acute, subacute, and chronic phases of care. Participants will gain practical insight into the recognition and management of CRS and ICANS, including escalation strategies for refractory cases and emerging complications such as HLH‑like syndromes. The session also addresses long‑term toxicities, survivorship considerations, and special populations.

Target Audience

This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

  1. Recognize signs and symptoms of cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) to facilitate prompt intervention and minimize patient morbidity.
  2. Demonstrate appropriate treatment of CRS and ICANS.
  3. Identify the long-term risks of CAR T-cell therapy, including persistent cytopenias, secondary malignancies, and late-onset organ dysfunction, to inform ongoing patient monitoring and management strategies.                             
Course summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

    Horizon CME designates this Enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Course opens: 
01/20/2026
Course expires: 
01/23/2027
Cost:
$0.00
Rating: 
0

Faculty

Brad Hunter, MD 

Director of Immune Effector Cell Therapy
Associate Professor
Intermountain LDS Hospital
Salt Lake City, UT

Brad Hunter is an Associate Professor of Research at Intermountain Health, where he directs the Immune Effector Cell (IEC) Therapy Program as well as the Oncology Research Program. The Intermountain IEC program covers a large geographic area (7 states) and treats a diverse group of patients, including those from urban, suburban, rural, and frontier settings. Since he began leading the program in 2019,they have rapidly expanded their standard of care and clinical trial footprint and have recently launched a remote apheresis and post-infusion care site in Saint George, more than 200 miles from their main hub in Salt Lake City. A central tenet of the mission of Intermountain Health is to treat patients where they live.

He has developed a robust outpatient CAR T program and has been able to mitigate toxicity to the point where the majority of their commercial CAR T patients are never admitted to the hospital. He has presented data from their patients at multiple national meetings and participated in multicenter consortiums to look for ways to maximize efficacy of CAR T while also working to minimize toxicity. Dr. Hunter has also published guidelines as part of an ASCO committee on Administration Safety Standards as the cellular therapy representative. 

Disclosures:

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous. 

All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.

Brad Hunter, MD   declares the following financial relationships in last 24 months:

  • Speakers Bureau: Genmab, AbbVie, Kite (These relationships have ended)
  • Advisory Boards: Kite, Novartis, BMS, Johnson & Johnson, ADC Therapeutics, Genmab, AbbVie, Genentech, Astellas, In8 Bio, Regeneron
  • Consulting Fee: Poseida Therapeutics, Caribou Biosciences
  • Contracted Research: Johnson and Johnson
  • Promotional Services Provided: Johnson and Johnson (This relationship has ended)

Available Credit

  • 0.75 AMA PRA Category 1 Credit™

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

    Horizon CME designates this Enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Price

Cost:
$0.00
Please login or register to take this course.

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the post-test
  4. Submit the evaluation form

DISCLAIMER:

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Required Hardware/software

Access to the internet is required.

Supported Browsers:

Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above

Google Chrome 28.0+ for Windows, Mac OS, or Linux

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux

Safari 6.0+ for Mac OSX 10.7 and above

 

Supported Phones & Tablets:

 Android 4.0.3 and above

iPhone/iPad with iOS 6.1 or above